Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01137526 | Efficacy and Safety Study of ABT-384 in Subjects With Mild-to-Moderate Alzheimer's Disease | PHASE2 | COMPLETED | 267 | — | — | May 1, 2010 | Jul 1, 2011 | Jan 29, 2013 | 30 | Russia, South Africa +2 |
| Arm | Type | Description |
|---|---|---|
| ABT-384 Dose 1 | EXPERIMENTAL | - |
| ABT-384 Dose 2 | EXPERIMENTAL | - |
| donepezil | ACTIVE_COMPARATOR | - |
| placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| ABT-384 | DRUG | Subjects will take study drug once daily for 12 weeks |
| donepezil | DRUG | Subjects will take study drug once daily for 12 weeks. |
| placebo | DRUG | Subjects will take study drug once daily for 12 weeks |
Inclusion Criteria: 1. The subject and caregiver must voluntarily sign and date and informed consent. If the subject is not fully competent, full informed consent must be obtained from a legal representative and assent must be obtained from the subject. 2. Subject is male or female between the ages...